REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Concerns about bribery allegations, angry CBS News staff and a looming high-stakes merger made for tense monthslong negotiations. The travel-review company's shares have fallen after it rejected ...

Stocks in the healthcare industry fell ahead of June's nonfarm payrolls, which economists surveyed by The Wall Street Journal expect to show declining job creation. Centene stock plummeted 40% after ...

This was the stock's third consecutive day of gains.

Regeneron Pharmaceuticals, Inc. (REGN) on Wednesday announced that the U.S. Food and Drug Administration has granted accelerated approval for its Lynozyfic to treat adult patients with relapsed or ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to buy 23andMe — the genetic testing company ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

IP litigation lawyers Joe Loy and Matt Hershkowitz discuss claim construction—one of the most important strategic decisions in patent litigation. The article delves into how various courts address ...

The invasive aspergillosis market is experiencing steady growth due to the rising prevalence of immunocompromised conditions such as cancer, organ transplantation, and chronic respiratory diseases.